title: [Propranolol in the treatment of problematic  infantile hemangiomas].
abstract: OBJECTIVE
  To evaluate the short-term efficacy and safety of propranolol for problematic infantile hemangiomas.
  
  
  METHODS
  Oral propranolol was administered to 68 infants with heamngiomas diagnosed by clinical evaluation and adjuvant examination at 1.0~2.0 mg per kilogram of body weight per day, divided to 2 or 3 times. The patients revisited once a month. The changes of the tumor size, texture, and color were monitored and recorded at a regular interval.The adverse effects after medication were observed and managed accordingly.The short-term results were evaluated using a 4-grade system.
  
  
  RESULTS
  All the 68 infants were followed up for 3-13 months, except that 1 infants combined with other diseases and 4 withdrew.The overall response was Scale 1 in 8 infants, Scale II in 13, Scale III in 29, and Scale IV in 13. No serious adverse effects were seen, but none cured entirely as well.
  
  
  CONCLUSIONS
  Oral propranolol is safe and effective for infantile heamngioma with good short-term result. It could be used as the primary drug for problematic infantile hemangiomas at the rapid growth stage of hemangiomas.
authors.affiliation: Department of Dermatology, Third Xiangya Hospital, Central South University, Changsha  410013, China.
authors.forename: Jianyun
authors.initials: J
authors.lastname: Lu
authors.forename: Guizhi
authors.initials: G
authors.lastname: Qin
authors.forename: Jinhua
authors.initials: J
authors.lastname: Huang
authors.forename: Suo
authors.initials: S
authors.lastname: Li
authors.forename: Jing
authors.initials: J
authors.lastname: Zhao
authors.forename: Yaping
authors.initials: Y
authors.lastname: Xiang
authors.forename: Jing
authors.initials: J
authors.lastname: Chen
authors.forename: Chengxin
authors.initials: C
authors.lastname: Zuo
authors.forename: Shengbo
authors.initials: S
authors.lastname: Yang
authors.forename: Lina
authors.initials: L
authors.lastname: Tna
mesh_terms: D005260:Female; D006391:Hemangioma / Q000188:drug therapy*; D006801:Humans; D007223:Infant; D008297:Male; D011433:Propranolol / Q000627:therapeutic use*; D011446:Prospective Studies; D012878:Skin Neoplasms / Q000188:drug therapy*; D040521:Subcutaneous Tissue
chemical_list: D011433:Propranolol